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ABSTRACT
with rheumatoid arthritis (RA) is thought to be increased
following anti-tumour necrosis factor (anti-TNF) therapy,
with a proposed differential risk between the anti-TNF
drugs etanercept (ETA), infliximab (INF) and adalimumab
(ADA).
to explore time to event, site of infection and the role of
ethnicity.
Biologics Register (BSRBR), a national prospective
observational study, were used to compare TB rates in
10 712 anti-TNF treated patients (3913 ETA, 3295 INF,
3504 ADA) and 3232 patients with active RA treated with
traditional disease-modifying antirheumatic drugs.
in the anti-TNF cohort. The rate of TB was higher for the
monoclonal antibodies ADA (144 events/100 000 person-
years) and INF (136/100 000 person-years) than for ETA
(39/100 000 person-years). After adjustment, the inci-
dence rate ratio compared with ETA-treated patients was
3.1 (95% CI 1.0 to 9.5) for INF and 4.2 (1.4 to 12.4) for
ADA. The median time to event was lowest for INF
(5.5 months) compared with ETA (13.4 months) and ADA
(18.5 months). 13/40 cases occurred after stopping
treatment. 25/40 (62%) cases were extrapulmonary, of
which 11 were disseminated. Patients of non-white
ethnicity had a sixfold increased risk of TB compared with
white patients treated with anti-TNF therapy.
with anti-TNF therapy was three- to fourfold higher in
patients receiving INF and ADA than in those receiving
ETA.
The introduction of anti-tumour necrosis factor
(anti-TNF) therapy has significantly advanced the
treatment of rheumatoid arthritis (RA). However,
despite good efficacy, there have always been
concerns about safety. A single case of tuberculosis
(TB) was reported in the first anti-TNF rando-
mised controlled trial.
1 Since then, there has been
accumulating evidence from spontaneous pharma-
covigilance studies that anti-TNF therapy increases
the risk of TB, with a possible differential risk
between the three anti-TNF drugs: infliximab
(INF) and adalimumab (ADA) (both monoclonal
antibodies) having a higher risk than etanercept
(ETA), a soluble TNF receptor.
2–5 This proposed
differential risk is supported by the report of
multiple cases of TB in RA clinical trials and
open-label extension studies of INF
1 6–8 and ADA
9–12
but only once within ETA publications.
13
Although the published data suggest a differen-
tial risk between drugs, studies to date do not
enable robust direct comparisons between drugs.
The aim of this study was first, to compare directly
the influence of the three licensed anti-TNF drugs
upon the incidence of TB in patients with RA, and
then to explore the magnitude of risk in anti-TNF
treated patients compared with patients with RA
treated with traditional disease modifying anti-
rheumatic drug (DMARD) therapy.
Secondary aims included exploring the time to
TB onset, the balance of pulmonary and extra-
pulmonary disease and the ethnicity of TB cases.
METHODS
The subjects for this analysis were participating in
a large national prospective observational study,
the British Society for Rheumatology Biologics
Register (BSRBR). The methods have been
described in detail elsewhere.
14 In brief, the study
was established in 2001 in order to examine the
long-term safety of biological drugs. UK national
guidelines recommended that ‘‘any clinician pre-
scribing these medications must (with the patient’s
permission) undertake to register the patient with
the BSRBR and forward information on dosage,
outcome and toxicity every 6 months’’.
15 Patients
were recruited to the ETA and INF cohorts from
2001 onwards. Recruitment to the ADA cohort
started later because of its more recent launch date.
Recruitment targets of 4000 patients for the ETA
cohort were met in 2005, for INF in 2007 and for
ADA in 2008. Before recruitment targets were met,
we estimated that .80% of anti-TNF-treated
patients with RA in the UK were registered on
the BSRBR.
Analysis was restricted to patients with a
doctor’s diagnosis of RA. All patients had to have
at least one returned consultant follow-up ques-
tionnaire before 31 March 2008. The anti-TNF
cohort comprised patients starting an anti-TNF
drug as their first biological drug. A comparison
cohort of biologic-naı ¨ve patients with active RA
was recruited in parallel (see authorship list of the
BSR Control Centre Consortium).
14 These patients
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had active disease despite current treatment with a traditional
DMARD and were biologic naı ¨ve.
Baseline assessment
Baseline information included demographics, disease duration,
28 swollen and tender joint counts, inflammatory markers and
patient global assessment, which enables calculation of a
Disease Activity Score (DAS28).
16 Self-reported ethnicity was
captured within the patient baseline questionnaire, then
categorised as white or non-white. Details of all previous and
current DMARD therapy were obtained, as well as smoking
history, comorbidity and prior TB. Data on screening for latent
TB were not requested. Patients completed a Health Assessment
Questionnaire adapted for British use.
17
Follow-up
Data on changes in treatment, disease activity and the
occurrence of adverse events were captured in three ways: 6-
monthly rheumatologist questionnaire, 6-monthly patient diary
and by ‘‘flagging’’ with the UK Office for National Statistics
which provided information on mortality, including cause of
death. If active TB was reported from any source, further
information, including site of infection and supporting evidence
for diagnosis (clinical/radiological/microbiological/histopatholo-
gical), was requested from the rheumatologist. Patient-reported
cases of TB were only included in the analysis if later verified by
a consultant.
Cases were categorised into ‘‘verified’’ or ‘‘unverified’’ TB by
three clinicians, including a consultant in infectious diseases
(WGD, JG and AU). Cases were ‘‘verified’’ if they were culture
positive and/or acid fast bacillus smear positive, or TB was
recorded on the death certificate. Cases of latent TB identified
from pretreatment screening were not included. The site of
infection was categorised as pulmonary (including pleural) or
extrapulmonary. All cases of miliary or disseminated TB were
categorised as extrapulmonary.
Statistical analysis
TB cases were attributed to anti-TNF therapy using two
different models: ‘‘on drug’’ (if the patient was actively
receiving that drug at the time of diagnosis) and ‘‘most recent
drug’’.
18 Follow-up was censored at the most recently completed
consultant follow-up or death, whichever came first. Patients
contributed follow-up time to the ‘‘on drug’’ model only while
they were actively receiving the drug (fig 1). The date of drug
discontinuation was taken as the first missed dose. Patients
could switch between different anti-TNF drugs and contribute
person-years to more than one drug. Follow-up was not
censored at the time of TB diagnosis. Patients could restart
treatment following an episode of TB, either resuming prior
treatment or switching drugs. Time following an episode of TB
was included to estimate risk reflecting clinical practice.
Sensitivity analyses were conducted excluding time after the
first diagnosis of TB, and restricting analyses to the first anti-
TNF drug.
Comparison patients also contributed person-years from their
registration date until their most recent completed consultant
follow-up or death, whichever came sooner. Patients in the
comparison cohort who switched to an anti-TNF drug
contributed person-years to the comparison cohort up to the
date the anti-TNF drug was started and subsequent follow-up
to the anti-TNF cohort. Conversely, patients initially registered
in the anti-TNF cohort could not subsequently contribute
person-years to the comparison cohort after stopping anti-TNF
therapy.
Incidence rates of TB are presented as events/100 000 person-
years with 95% confidence intervals (95% CI). Incidence rate
ratios (IRRs) were calculated using Cox regression, comparing
between anti-TNF drugs with ETA as the referent group.
Comparison was then made between the anti-TNF cohort and
the DMARD cohort. Adjustment was made for age, gender and
calendar year of recruitment. In the absence of cases in the
DMARD cohort, an ‘‘expected’’ number of cases was generated
using indirect standardisation: assuming the DMARD cohort
shared the same risk as the anti-TNF cohort, allowing for
differences in age, gender and calendar year. Analyses examining
the influence of ethnicity were performed after adjustment for
age, gender and calendar year and after exclusion of patients
with missing ethnicity data. Multiple variable regression was
performed with additional confounders identified from an a
priori list of possible confounders, including smoking, diabetes,
chronic obstructive pulmonary disease/asthma, prior TB,
disease severity (Health Assessment Questionnaire, DAS28
and disease duration as continuous variables), number of prior
DMARDs, baseline steroid use, and methotrexate use (as a time-
varying covariate). True confounders were identified by
sequentially including each confounder in the regression model,
and including in the multiple variable regression those
confounders that individually changed the estimation after
adjustment by more than 10%.
19 All analysis was done using
Stata 9.2 (StataCorp, College Station, Texas, USA).
RESULTS
A total of 13 739 patients were included in the analysis: 3232 in
the DMARD cohort and 10 712 in the anti-TNF cohort. Two
hundred and five patients switched from the DMARD cohort to
the anti-TNF cohort and contributed person-years to both
cohorts. A total of 2552 (24%) patients received two anti-TNF
drugs, and 416 (4%) received all three. Table 1 shows the
baseline characteristics. The anti-TNF cohort was younger,
comprised proportionally more women and, as expected, had
more severe disease than the comparison cohort. Proportionally
more patients treated with ETA had prior TB (2.5%) than those
treated with INF or ADA (1.5%). Proportionally fewer in the
DMARD cohort were of non-white origin.
Total follow-up time was 7345 person-years for the DMARD
cohort and 34 025 person-years for the anti-TNF cohort, with
28 447 person-years spent actively receiving anti-TNF therapy.
The median duration of follow-up per patient was 3.21 years for
the anti-TNF cohort and 2.30 years for the DMARD cohort. The
median duration ‘‘on drug’’ was 2.48 years for ETA, 1.68 years
for INF and 1.26 years for ADA.
There were 40 episodes of doctor-reported active TB in 39
patients, all in the anti-TNF cohort (see online supplemen-
tary table S1). There were no cases in the DMARD cohort.
Thirteen of 40 episodes occurred after discontinuation of the
anti-TNF drug. The numbers and rates for the two models of
risk attribution are reported in table 2, with the cumulative
incidence shown in fig 2. Of the 13 cases that occurred ‘‘off
drug’’, seven were diagnosed within 90 days of stopping
treatment. In these cases, the drug was often stopped for
symptoms of TB, although the diagnosis was made only after
drug discontinuation. One case was diagnosed 6.0 months
after stopping ETA, one 11.5 months after stopping INF, and
four cases after stopping ADA (3.6, 7.3, 12.9 and
13.8 months).
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Between-drug comparisons
Using the ‘‘on drug’’ model of attributing risk (upper half of
table 2), the rate of TB was highest for ADA (144 events/
100 000 person-years), followed by INF (136/100 000 person-
years) then ETA (39/100 000 person-years). Compared with
ETA, the adjusted IRRs (aIRRs) and 95% CI for ADA and INF
were 4.2 (1.4 to 12.4) and 3.1 (1.0 to 9.5), respectively. In the
‘‘most recent drug’’ model (lower half of table 2) the aIRRs
remained higher for both INF and ADA compared with ETA,
although the magnitude of the effect size fell for INF
(aIRR=2.2 (0.9 to 5.8)). Censoring follow-up at the date of
first TB diagnosis did not change the effect size (data not
shown). None of the potential confounders changed the point
estimate by .10%, and were therefore not included in the
regression model. Age and ethnicity were the only potential
confounders that were significantly associated with TB
(irrespective of their influence upon change in the point
estimate).
Comparison of the anti-TNF and DMARD cohorts
No direct comparison between the anti-TNF cohort and the
DMARD cohort could be made owing to the absence of cases in
the DMARD cohort. Indirect standardisation was performed,
assuming the DMARD cohort shared the same risk as the anti-
TNF cohort. After allowing for differences in age, gender and
calendar year, the expected rate in the DMARD cohort was 136
events/100 000 person-years (65 to 250), equating to 10.0 cases.
This was significantly more than the observed 0 cases (one-sided
p value ,0.001). Indirect standardisation was also performed
assuming the DMARD cohort shared the same risk as the ETA-
treated cohort. After allowing for differences in age, gender and
calendar year, the expected rate was 41 cases/100 000 person-
years (8 to 119), equating to 3.1 cases (also significantly
increased, p=0.045).
Sensitivity analyses
Twenty-four of 40 (60%) cases were categorised as ‘‘verified’’
and 16 as ‘‘unverified’’. Of the 24 verified cases, two were most
recently treated with ETA, nine with INF and 13 ADA.
Between-drug comparisons led to a statistically significantly
increased rate of TB for both monoclonal antibodies compared
with ETA, using the ‘‘most recent drug’’ model.
Seven cases of TB occurred after treatment with a second or
third anti-TNF drug. Of these, two occurred with ADA, one
with ETA, three after discontinuing ADA and one after
discontinuing ETA. When sensitivity analyses were performed
excluding time periods following switching (table 3), the
between-drug aIRRs were largely unchanged.
Time to event
The median time to TB diagnosis from the start of first anti-
TNF drug was 13.4 months for cases most recently exposed to
ETA, 5.5 months for INF and 18.5 months for ADA. Because
patients could switch between drugs, the time from start date
of first drug does not always reflect time since starting the most
recent drug. In the sensitivity analysis excluding time periods
after the start of a second anti-TNF drug, the median times to
event were 11.0, 5.5 and 15.0 months for ETA, INF and ADA,
respectively (fig 2). The differences in time to diagnosis between
the three drugs for both analyses were statistically significant
(p,0.05) using a Kruskal–Wallis test.
Site of TB
Fifteen of 40 cases (38%) were pulmonary and 25 (62%)
extrapulmonary (table 4). Eleven (28%) were disseminated. A
lower proportion (50%) of the TB cases after exposure to ETA
was extrapulmonary than with INF (67%) and ADA (65%).
Eight of 20 (40%) cases in the ADA cohort were disseminated,
compared with 2/12 (17%) and 1/8 (13%) in the INF- and ETA-
treated cohorts, respectively.
Influence of ethnicity
Ethnicity data were available for 32/39 patients who developed
TB. Twenty-six (65%) were white and six (15%) non-white.
This compared with around 80% patients who were white and
2–3% non-white in the original DMARD and anti-TNF
populations. After excluding patients with missing ethnicity
data, the age-, sex- and calendar year-adjusted IRR for active TB
Figure 1 Models for attributing tuberculosis (TB) to drug treatment. (A)
‘‘On drug’’. Patient-years and adverse events were attributed to each
drug only while the patient was actively receiving that drug. Event A was
not attributed to any drug, while event B was attributed to drug 2. (B)
‘‘Most recent drug’’. Patient-years were accrued for each drug from the
start date of that drug until the date of switching to the next anti-tumour
necrosis factor drug, irrespective of drug discontinuation. Follow-up was
censored at the most recently completed consultant follow-up or death,
whichever came first, for all models.
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in non-white compared with white patients was 6.5 (2.8 to
15.3).
Ten of 39 patients who developed active TB died within
12 months of diagnosis date. Seven of these had TB listed on
their death certificates as the underlying or contributory cause
of death (see online supplementary table S1).
One patient had two discrete episodes of TB. A 30-year-old
white woman developed verified TB in a cervical lymph node
10 months into treatment with ADA. Her ADA was discon-
tinued and she was treated with Rifinah, pyridoxine and
ethambutol for 6 months, with confirmed antibiotic sensitivity.
Seventeen months later, without any additional anti-TNF
Table 1 Baseline characteristics
Characteristics
DMARD
(n=3232)*
All anti-TNF
(n=10 712)* p Value{
First anti-TNF drug:
p Value{
ETA
(n=3913)
INF
(n=3295)
ADA
(n=3504)
Age (years), mean (SD) 60 (12) 56 (12) ,0.001 56 (12) 56 (12) 57 (12) 0.012
Women (%) 72 76 ,0.001 77 76 75 0.108
DAS28, mean (SD) 5.1 (1.3) 6.6 (1.0) ,0.001 6.6 (1.0) 6.6 (1.0) 6.5 (1.0) ,0.001
HAQ, mean (SD) 1.5 (0.8) 2.0 (0.6) ,0.001 2.1 (0.6) 2.1 (0.5) 2.0 (0.6) ,0.001
Disease duration (years),
median (IQR)
6 (1–15) 11 (6–19) ,0.001 12 (6–19) 12 (6–19) 10 (5–18) ,0.001
Number of prior DMARDs,
median (IQR)
2 (1–3) 4 (3–5) ,0.001 4 (3–5) 4 (3–5) 3 (3–5) ,0.001
Baseline steroid use, n (%) 744 (23) 4753 (44) ,0.001 1860 (48) 1520 (46) 1373 (39) ,0.001
Diabetes, n (%) 212 (6.6) 596 (5.6) 0.034 236 (6.1) 156 (4.8) 204 (5.9) 0.042
COPD/asthma, n (%) 590 (18.4) 1429 (13.5) ,0.001 558 (14.4) 423 (13.0) 448 (12.9) 0.104
Prior TB, n (%) 74 (2.3) 201 (1.8) 0.193 96 (2.5) 53 (1.5) 52 (1.5) 0.05
Smoking, n (%)
Current 751 (23) 2334 (22) 0.013 805 (21) 718 (22) 811 (23) 0.057
Former 1273 (40) 4067 (38) 1485 (38) 1247 (38) 1335 (38)
Never 1191 (37) 4249 (40) 1599 (41) 1314 (40) 1336 (38)
Ethnicity, n (%)
White 2509 (78) 8873 (83) ,0.001 3228 (82) 2704 (82) 2941 (84) 0.363
Non-white 59 (2) 366 (3) 124 (3) 124 (4) 118 (3)
Missing 664 (21) 1473 (14) 561 (14) 467 (14) 445 (13)
Entry year, n (%)
Before 2003 11 (0) 1322 (12) ,0.001 181 (5) 1112 (34) 29 (1) ,0.001
2003 306 (9) 2924 (27) 1440 (37) 1063 (32) 421 (12)
2004 886 (27) 3092 (29) 1876 (48) 485 (15) 731 (21)
2005 925 (29) 1537 (14) 412 (11) 326 (10) 799 (23)
2006+ 1104 (34) 1837 (17) 4 (0) 309 (10) 1524 (43)
*Two hundred and five patients switched from the DMARD cohort to the anti-TNF cohort and contributed person-years to both cohorts; {p value represents the significance of
differences between the DMARD and anti-TNF cohorts using x
2 tests for categorical outcomes and Wilcoxon rank sum tests for continuous variables; {p value represents the
significance of differences between the three anti-TNF drugs using x
2 tests for categorical outcomes and Kruskal–Wallis rank tests for continuous variables.
ADA, adalimumab; COPD, chronic obstructive pulmonary disease; DAS28, 28 joint count Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; ETA, etanercept;
HAQ, Health Assessment Questionnaire; INF, infliximab; TB, tuberculosis; TNF, tumour necrosis factor.
Table 2 Numbers and rates of incident tuberculosis, switchers included
Number of patients
ever received the drug
DMARD
(n=3232)
All anti-TNF
(n=10 712)
ETA
(n=5521)
INF
(n=3718)
ADA
(n=4857)
On drug*
Person-years 7345 28 447 12 744 8069 7634
Cases of TB 0 27 5 11 11
Rate/100 000 person-
years (95% CI)
0 95 (63 to 138) 39 (13 to 92) 136 (68 to 244) 144 (72 to 258)
IRR, adjusted for age,
gender and entry year
(95% CI)
Referent 3.1 (1.0 to 9.5) 4.2 (1.4 to 12.4)
Most recent drug*
Person-years 7345 34 025 15 070 9730 9224
Cases of TB 0 40 8 12 20
Rate/100 000 person-
years (95% CI)
0 118 (84 to 160) 53 (23 to 105) 123 (64 to 215) 217 (132 to 335)
IRR, adjusted for age,
gender and entry year
(95% CI)
Referent 2.2 (0.9 to 5.8) 4.2 (1.8 to 9.9)
Patients could switch between anti-TNF therapies, but all TB cases were attributable to one drug only
*The two models of risk attribution are illustrated in fig 1.
ADA, adalimumab; DMARDs, disease-modifying antirheumatic drugs; ETA, etanercept; INF, infliximab; IRR, incidence rate ratio; TB,
tuberculosis; TNF, tumour necrosis factor.
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therapy, she was diagnosed with verified pulmonary TB.
Mycobacterial interspersed repetitive unit typing confirmed
this second episode as a relapse of the first.
DISCUSSION
We have confirmed that the monoclonal antibodies INF and
ADA are associated with a three- to fourfold higher rate of TB
compared with ETA. Although no direct comparison with the
DMARD cohort was possible, the expected number of cases
(n=10) in the DMARD cohort based on the rate seen in the
anti-TNF cohort versus the observed (n=0) suggests that anti-
TNF therapy confers a significant risk in patients with active
RA. The combined strengths of the large size of the study with
the accurate capture of time-dependent drug use and serious
adverse event data enabled a robust direct comparison of the
rates of TB between the three anti-TNF drugs.
Before concluding that these estimated relative risks represent
a true differential risk between the drugs, we should explore
alternative explanations. ADA was licensed later, and thus
patients receiving ADA may have been more likely to have
already received other anti-TNF drugs. Some risk of TB may be
carried over from the previous drug, and sequential drug use
may have a multiplicative risk. However, the sensitivity analysis
censoring follow-up at switching did not change the results.
Other factors that may influence the drug-specific rates include
calendar year of drug start in parallel with the increasing
background UK population rate of TB (12.3 to 14.7 events/
100 000 person-years from 2001 to 2005
20) and increasing
awareness of, and changing UK guidelines for, TB screening.
21
This was addressed by adjusting all analyses for calendar year of
recruitment. Nonetheless, there may be some residual con-
founding.
It has been suggested that there may be a time-varying risk of
TB with anti-TNF therapy, with a higher early increased risk for
INF than for ETA.
5 Different average durations of follow-up by
drug may influence our rate estimates if the risk of TB is non-
linear. However, limiting analysis to the first year of follow-up
would result in too few cases to allow meaningful comparison
between the drugs.
The early belief that the risk of TB was greater for INF-
treated than for ETA-treated patients may have led to a
selection bias, where clinicians preferentially prescribed ETA to
patients at higher risk of TB. Indeed, proportionally more
patients treated with ETA had prior TB, supporting this
hypothesis. Assuming no effect of anti-TNF therapy, we might
thus expect a higher rate of TB in ETA-treated patients. Our
results show the opposite, meaning such a treatment bias does
not account for our findings.
Our study did not capture data on all the known risk factors
for TB. We did not have data on nutritional status, substance
misuse, living environment (eg, residential care), contact with
TB, vitamin D deficiency or immunodeficiency states such as
HIV.[22] However, it is unlikely that these factors were more
prevalent in the monoclonal antibody-treated patients than in
the ETA cohort.
Figure 2 Cumulative incidence of tuberculosis (TB) following first
exposure to anti-tumour necrosis factor (anti-TNF) therapy (most recent
drug model, with person-years censored at death, last returned follow-up
form, or date of switching to second anti-TNF). Numbers in table
represent the number of patients eligible for follow-up at the specified
follow-up time points. ADA, adalimumab; DMARD, disease-modifying
antirheumatic drug; ETA, etanercept; INF, infliximab.
Table 3 Numbers and rates of incident tuberculosis, limited to first anti-TNF drug. (Follow-up censored at
date of starting second anti-TNF drug)
Number of patients ever
received the drug
DMARD
(n=3232)
All anti-TNF
(n=10 712)
ETA
(n=3913)
INF
(n=3295)
ADA
(n=3504)
On drug*
Person-years 7345 23 286 10 111 7459 5716
Cases of TB 24 4 11 9
Rate/100 000 person-
years (95% CI)
103 (66 to 153) 40 (11 to 101) 147 (74 to 264) 157 (72 to 299)
IRR, adjusted for age,
gender and entry year
(95% CI)
Referent 3.7 (1.1 to 12.7) 4.4 (1.3 to 15.2)
Most recent drug*
Person-years 7345 27 624 11 926 8963 6735
Cases of TB 33 6 12 15
Rate/100 000 person-
years (95% CI)
119 (82 to 168) 50 (18 to 110) 134 (69 to 234) 223 (125 to 367)
IRR, adjusted for age,
gender and entry year
(95% CI)
Referent 2.7 (0.9 to 7.8) 4.4 (1.6 to 12.1)
*The two models of risk attribution are illustrated in fig 1.
ADA, adalimumab; DMARDs, disease modifying antirheumatic drugs; ETA, etanercept; INF, infliximab; IRR, incidence rate ratio; TB,
tuberculosis; TNF, tumour necrosis factor.
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Comparing our results with the published literature, we
found that there are few studies attempting to examine the
question of drug-specific risk. Limitations of prior studies
include imprecise estimates of rates in spontaneous pharmaco-
vigilance studies, owing to under-reporting of cases and an
unknown denominator
45 and low numbers of events in
observational studies.
23 24 The French RATIO study recently
attempted to examine drug-specific risk by calculating event
‘‘rates’’ from spontaneously reported cases of TB and estimates
of national anti-TNF drug use across all indications.
25 Our
findings support the original suggestion that the rate of TB may
be higher in INF-treated than in ETA-treated patients,
32 6
although to a lesser extent than the French study.
25 Our finding
that TB rates are highest in patients treated with ADA is
supported by a high rate of TB in the ADA open-label extension
study.
12 The possible mechanisms underlying this differential
risk of TB have been elegantly reviewed elsewhere.
27
Active TB was diagnosed only in patients treated with anti-
TNF therapy. If patients in the DMARD cohort had an equal
risk to those in the anti-TNF cohort, we would have expected to
see 10 TB cases in the DMARD cohort. The magnitude of
difference between the observed and expected cases strongly
suggests that anti-TNF therapy is associated with significant
risk of TB above and beyond the risk conferred by RA alone. The
indirect standardisation data also support an increased risk for
ETA, where the expected number of cases in the DMARD
cohort would have been 3.1. This finding suggests that,
although the rates of TB are higher in patients treated with
the monoclonal antibodies, patients treated with ETA are not
without risk. The average annual incidence of TB for the period
of the study in the UK general population was 13.2 events/
100 000 person-years.
20 The anti-TNF rate was therefore eight
times higher than in the UK general population. The magnitude
of increased risk is higher than the estimated fourfold increased
risk conferred by RA in the prebiologic era from non-UK
sources.
24 Unfortunately, there are no previously published rates
of TB in UK RA populations from the pre-biologic era. Because
of widely varying international TB incidence, it is not valid to
compare our rates with those in other national RA cohorts.
Nonetheless, the magnitude of risk in the anti-TNF cohort
compared with the general population fits with prior estimates
from other countries.
23 28
All TB cases in the analysis were confirmed by a doctor. The
‘‘gold standard’’ for diagnosing TB is culture of Mycobacterium
tuberculosis bacilli. However, in clinical practice, doctors
diagnose and treat TB based on weaker criteria such as the
presence of acid fast bacilli, caseating granulomata, suggestive
radiological findings, or even clinical suspicion. We categorised
our cases as verified or unverified. Our tight classification for
verified TB led to the exclusion of 16 cases. Nonetheless,
restriction to verified cases generated the same pattern of drug-
specific risk.
Prior estimates of the frequency of extrapulmonary TB in
patients treated with anti-TNF therapy have ranged from 28%
to 75%, with most reporting .50% cases as extrapulmonary.
Our study replicates these findings, but in addition shows a
greater increased risk of extrapulmonary disease with the
monoclonal antibodies, a finding not previously described.
Our finding of a significant risk conferred by non-white
ethnicity in patients treated with anti-TNF therapy also reflects
similar findings in the RATIO study.
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There are a number of clinically important points to take
from this analysis. First, although the relative risk of TB is three
to four times higher for the monoclonal antibodies than for
ETA, the actual number of cases is low. After a total follow-up
time of nearly 35 000 person-years, we identified only 40 cases
of TB. The ‘‘number needed to harm’’ for 1 year’s therapy with
ADA compared with ETA in this study is around 600. That said,
the UK is a country with a relatively low prevalence of TB. Such
a differential risk would probably have greater implications in
countries with higher background prevalence. Second, the lower
rate with ETA compared with the other anti-TNF drugs does
not mean that there is a negligible risk with this drug. Although
relatively safer than the monoclonal antibodies, clinicians
should be aware that ETA still confers an increased risk.
Third, the high prevalence of disseminated TB should remind
clinicians that TB may present atypically in patients treated
with anti-TNF therapy. Lastly, nearly half of the disseminated
TB cases in patients most recently treated with ADA occurred
after treatment had been stopped, with 13 of the total cases
being diagnosed after stopping treatment (6/13 .3 months
after stopping). This should remind clinicians to remain vigilant
for TB even after discontinuing anti-TNF therapy.
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Pharyngeal wall – – 1 {1} 1 {1}
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